LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Akcijų sąrašas・Sana Biotechnology Inc

Sana Biotechnology Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

3.05 0.33

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.01

Max

3.22

Pagrindiniai rodikliai
By Trading Economics
Pajamos	12M -47M
Pelnas, tenkantis vienai akcijai	-0.171
Darbuotojai	142
EBITDA	23M -35M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+184.59% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-115M 846M
Ankstesnė atidarymo kaina	2.72
Ankstesnė uždarymo kaina	3.05

Naujienos nuotaikos

By Acuity

25%

75%

49 / 344 reitingas Healthcare

Sana Biotechnology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-26 16:52; UTC

Svarbiausios naujienos

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

2026-05-26 23:57; UTC

Uždarbis

Sociedad Quimica 1Q Rev $1.76B >SQM

2026-05-26 23:57; UTC

Uždarbis

Sociedad Quimica 1Q EPS $1.28 >SQM

2026-05-26 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

2026-05-26 21:54; UTC

Uždarbis

Webco Industries 3Q EPS $11.61 >WEBC

2026-05-26 21:54; UTC

Uždarbis

Webco Industries 3Q Sales $179.6M >WEBC

2026-05-26 21:48; UTC

Rinkos pokalbiai

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

2026-05-26 21:00; UTC

Rinkos pokalbiai

ESG Roundup: Market Talk

2026-05-26 20:58; UTC

Įsigijimai, susijungimai, perėmimai

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

2026-05-26 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-26 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-05-26 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-26 19:22; UTC

Rinkos pokalbiai

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

2026-05-26 19:17; UTC

Rinkos pokalbiai

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

2026-05-26 18:56; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

2026-05-26 18:03; UTC

Rinkos pokalbiai

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

2026-05-26 17:42; UTC

Rinkos pokalbiai

Grains Await Fresh Trading Catalyst -- Market Talk

2026-05-26 17:33; UTC

Rinkos pokalbiai

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

2026-05-26 17:21; UTC

Rinkos pokalbiai

Canada Faces a Labor Market Squeeze -- Market Talk

2026-05-26 16:52; UTC

Rinkos pokalbiai

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

2026-05-26 16:43; UTC

Rinkos pokalbiai

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

2026-05-26 16:24; UTC

Rinkos pokalbiai

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

2026-05-26 16:21; UTC

Rinkos pokalbiai

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

2026-05-26 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-26 16:20; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-05-26 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-26 16:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Auto & Transport Roundup: Market Talk

2026-05-26 16:16; UTC

Rinkos pokalbiai

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

2026-05-26 16:01; UTC

Rinkos pokalbiai

Bitcoin Lower as Stress Builds for Holders -- Market Talk

2026-05-26 15:21; UTC

Rinkos pokalbiai

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Akcijų palyginimas

Kainos pokytis

Sana Biotechnology Inc Prognozė

Kainos tikslas

By TipRanks

184.59% į viršų

12 mėnesių prognozė

Vidutinis 8.68 USD 184.59%

Aukščiausias 16 USD

Žemiausias 3.07 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sana Biotechnology Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

7 ratings

Pirkti

Laikyti

Parduoti

Remiantis 7 analitikų, pateikusių Sana Biotechnology Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

49 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.